Clinical Laboratory for Epidemiology & Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
University of Texas Southwestern Medical School, Dallas, TX 75390, USA.
Immunotherapy. 2023 Dec;15(17):1449-1457. doi: 10.2217/imt-2023-0103. Epub 2023 Oct 16.
The IL-17 pathways are involved in the pathophysiology of many inflammatory skin conditions, including hidradenitis suppurativa. Secukinumab, an IL-17A inhibitor, has been used for years in inflammatory skin disorders such as psoriasis. To date, the only US FDA-approved medication for hidradenitis suppurativa is adalimumab, a TNF-α inhibitor. Recently, secukinumab has demonstrated promising results in the treatment of hidradenitis suppurativa in the phase III SUNSHINE and SUNRISE clinical trials. This article reviews the mechanism of action of secukinumab and summarizes the available clinical efficacy and safety data regarding secukinumab in the management of hidradenitis suppurativa.
IL-17 通路参与许多炎症性皮肤疾病的病理生理学，包括化脓性汗腺炎。司库奇尤单抗是一种 IL-17A 抑制剂，多年来一直用于治疗银屑病等炎症性皮肤疾病。迄今为止，美国食品药品监督管理局批准用于化脓性汗腺炎的唯一药物是 TNF-α 抑制剂阿达木单抗。最近，司库奇尤单抗在 III 期 SUNSHINE 和 SUNRISE 临床试验中显示出治疗化脓性汗腺炎的良好效果。本文综述了司库奇尤单抗的作用机制，并总结了其在化脓性汗腺炎治疗中的临床疗效和安全性数据。
